Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model.

Abstract

PURPOSE:

We analyzed the effect of intraperitoneal immunotherapy in an animal model mimicking locoregional dissemination of tumor cells during resection of advanced tumors.

METHODS:

We first established a tumor model with human gastric cancer cells (MKN-45) in the peritoneal cavity of CB-17-SCID mice. Three hours following the injection of tumor cells into the peritoneal cavity, mAb 17-1A alone and in combination with human LAK cells were given intraperitoneally at different dosages. The results were quantified by determining the weight of the peritoneal tumor masses.

RESULTS:

After intraperitoneal administration of 17-1A mAb, a tumor reduction could be shown (median tumor mass after 10 microg mAb: 171 microg; after 100 microg: 130 microg) when compared with the control group (632 microg). Following a combined therapy with mAb and LAK cells, a statistically significant tumor reduction could be observed (after 10 microg mAb + 20-50 x 10(6) LAK cells: 80 microg; after 100 microg mAb + 20-50 x 10(6) LAK cells: 12 microg, p = 0.0005). With specific dosages of antibody and LAK cells it was even possible to achieve complete tumor clearance.

CONCLUSIONS:

Intraperitoneal immunotherapy reduces the peritoneal tumor masses and can even prevent the peritoneal carcinomatosis formation.

• Authors: P Piso, H Aselmann, R von Wasielewski, M H Dahlke, J Klempnauer, H J Schlitt
• Journal: European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes (Eur Surg Res) 2003 Nov-Dec Vol. 35 Issue 6 Pg. 470-6 ISSN: 0014-312X [Print] Switzerland
• PMID: 14593230 (Publication Type: Journal Article)
• Copyright: Copyright 2003 S. Karger AG, Basel

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Edrecolomab

Topics

• Animals
• Antibodies, Monoclonal (pharmacology)
• Antibodies, Monoclonal, Murine-Derived
• Disease Models, Animal
• Female
• Humans
• Immunotherapy
• Injections, Intraperitoneal
• Killer Cells, Lymphokine-Activated (transplantation)
• Mice
• Mice, SCID
• Middle Aged
• Peritoneal Neoplasms (immunology, prevention & control, therapy)
• Stomach Neoplasms (immunology, prevention & control, therapy)
• Xenograft Model Antitumor Assays